Research programme: anti-CD55 monoclonal antibodies - Viragen

Drug Profile

Research programme: anti-CD55 monoclonal antibodies - Viragen

Alternative Names: CD55 cancer vaccine - Viragen Scotland; CD55 vaccine - Viragen Scotland; VG 102

Latest Information Update: 04 Feb 2008

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cancer Research Technology; University of Nottingham
  • Developer Viragen Scotland
  • Class Monoclonal antibodies
  • Mechanism of Action CD55 antigen inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 06 Jun 2007 This programme is still in active development
  • 09 May 2005 The anti-CD55 antibody has been licensed to Viragen worldwide
  • 21 Mar 2005 Preclinical data from a media release have been added to the Cancer pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top